Advertisement
U.S. Markets open in 49 mins
Advertisement

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
814.86-8.95 (-1.09%)
At close: 04:00PM EST
814.86 0.00 (0.00%)
Pre-Market: 08:00AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close823.81
Open824.94
Bid750.05 x 800
Ask0.00 x 1000
Day's Range808.89 - 828.12
52 Week Range668.00 - 853.97
Volume560,248
Avg. Volume447,998
Market Cap88.777B
Beta (5Y Monthly)0.14
PE Ratio (TTM)23.26
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
1% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for REGN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Regeneron Pharmaceuticals, Inc.
    Analyst Report: Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
    Rating
    Fair Value
    Economic Moat
    last monthMorningstar
View more